BioCentury | Mar 31, 2014
Emerging Company Profile

ImmuSmol: Going small

...enzymes that produce small molecule metabolites capable of blocking T cells in the tumor microenvironment. ImmuSmol S.A.S....
...not been widely harnessed therapeutically because of technical challenges in constructing the appropriate target-carrier conjugates, ImmuSmol...
...a good epitope." Designing and synthesizing conjugates that elicit the desired antibodies in mice constitute ImmuSmol's...
Items per page:
1 - 1 of 1
BioCentury | Mar 31, 2014
Emerging Company Profile

ImmuSmol: Going small

...enzymes that produce small molecule metabolites capable of blocking T cells in the tumor microenvironment. ImmuSmol S.A.S....
...not been widely harnessed therapeutically because of technical challenges in constructing the appropriate target-carrier conjugates, ImmuSmol...
...a good epitope." Designing and synthesizing conjugates that elicit the desired antibodies in mice constitute ImmuSmol's...
Items per page:
1 - 1 of 1